Open AccessTHE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
Author(s) -
К. Б. Мирзаев,
D.A. Sychev Sychev,
Д. А. Андреев,
A. B. Prokofiev
Publication year - 2013
Publication title -
racionalʹnaâ farmakoterapiâ v kardiologii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.161
H-Index - 9
eISSN - 2225-3653
pISSN - 1819-6446
DOI - 10.20996/1819-6446-2013-9-4-404-408
Subject(s) - cyp2c19 , medicine , clopidogrel , pharmacogenetics , clinical practice , active metabolite , clinical significance , antiplatelet drug , drug , cardiology , intensive care medicine , pharmacology , aspirin , metabolite , physical therapy , genotype , biochemistry , chemistry , cytochrome p450 , metabolism , gene